Takeyasu Y, Yoshida T, Shibaki R, Matsumoto Y, et al. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS >/= 50%) NSCLC. Clin Lung Cancer 2021;22:127-133.
PMID: 33183972